Tillotts Pharma AG announces the launch of Octasa® 800mg Tablets in Canada

Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce the recent launch of Octasa® 800mg (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada.

The launch of Octasa® 800mg represents an important step in Tillotts’ strategic partnership with Pendopharm, Division of Pharmascience Inc. Canada and a milestone for both organisations.

Canada has one of the highest incidences of ulcerative colitis in the world, with 7 in 1,000 Canadians affected by the disease. By 2030, the incidence of UC in Canada is expected to rise to 1% or 1 in 100 (403,000 Canadians)¹.

The introduction of Octasa® 800mg (mesalazine) delayed-release tablets to the Canadian market is expected to optimise the therapeutic options for Inflammatory Bowel Disease (IBD) in Canada.

Adrian Hill, Global Head of Commercial Operations at Tillotts, said:
“We are very excited to announce that Octasa® 800mg from Tillotts AG is now available in Canada. The commercial launch of Octasa® 800mg tablets in Canada will bring a new treatment option in the form of a tablet to clinicians and patients. This has been achieved through the strong strategic partnership between Tillotts and Pendopharm.”

Jad Isber, Vice President and General Manager at Pendopharm, added:
“We are delighted to continue our strong relationship with Tillotts by bringing Octasa® 800mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa® 800mg to our portfolio will further enhance Pendopharm’s leadership position in GI, bringing a new treatment option to healthcare professionals and patients.”